Michael David David

US Patent:

7811996, Oct 12, 2010

Filed:

Nov 1, 2002

Appl. No.:

10/494452

Inventors:

Michael David - San Diego CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/05

US Classification:

514 25, 514120, 514646, 514733

Abstract:

The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.

US Patent:

8080527, Dec 20, 2011

Filed:

Jul 26, 2010

Appl. No.:

12/843410

Inventors:

Michael David - San Diego CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/05

US Classification:

514 25, 514720, 514733, 514646

Abstract:

The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.

US Patent:

8415323, Apr 9, 2013

Filed:

Aug 27, 2008

Appl. No.:

12/675368

Inventors:

Michael David - San Diego CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A01N 43/04
A01N 63/00
A61K 48/00
A61K 31/70

US Classification:

514 55, 424 932, 435455, 435 61, 514 44 A

Abstract:

The present invention relates to reducing accumulation of viral genomes in a target cell. In particular the present invention provides compositions and methods for combating viral infection through RNA interference. Specifically the present invention provides cellular microRNA mimics for treating virus-infected subjects.

US Patent:

8455553, Jun 4, 2013

Filed:

Nov 10, 2011

Appl. No.:

13/293876

Inventors:

Michael David - San Diego CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/09
A61P 29/00

US Classification:

514720, 514733

Abstract:

The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.

US Patent:

20110123524, May 26, 2011

Filed:

Jan 22, 2009

Appl. No.:

12/919708

Inventors:

Michael David - San Diego CA, US
Irene Munk Pedersen - La Jolla CA, US

International Classification:

A61K 39/395
A61K 38/17
A61P 35/00
A61P 35/02

US Classification:

4241331, 4241581, 514 193, 4241421, 514 196

Abstract:

The present invention relates to methods for treating neoplasias in a mammalian subject. In particular, the invention provides methods for treating lymphomas, including forms of non- Hodgkin lymphoma. In one embodiment, these methods involve reducing tumor necrosis factor signaling.

US Patent:

20130086705, Apr 4, 2013

Filed:

Sep 21, 2012

Appl. No.:

13/624153

Inventors:

Michael David - San Diego CA, US
Manqing Li - San Diego CA, US

International Classification:

C12N 5/07

US Classification:

800 11, 514 44 A, 435 79, 435 5, 435 611, 435455, 435325

Abstract:

The invention provides methods and compositions for screening candidate compounds for activity in altering the level of expression of Schlafen (Slfn) in cells, tissues and animals. The invention also provides methods and compositions for screening candidate compounds for activity in altering the level of virus infection. The invention further provides methods and compositions for screening candidate compounds for altering the level of expression of virus proteins without substantially unfaltering the level of expression of cellular proteins. The invention additionally provides methods and compositions for diagnosing the risk and/or susceptibility to virus infection. The invention also provides transgenic non-human animals, and transgenic cells, comprising a mutant Schlafen (Slfn) gene, such as a knockout mutation. These invention's compositions and methods are useful as models for virus infection, and for screening candidate prophylactic and/or therapeutic anti-viral compounds.

US Patent:

20130253071, Sep 26, 2013

Filed:

Mar 14, 2013

Appl. No.:

13/804820

Inventors:

Michael David - San Diego CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/05

US Classification:

514733

Abstract:

The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.

US Patent:

56258127, Apr 29, 1997

Filed:

Nov 14, 1994

Appl. No.:

8/339454

Inventors:

Michael M. David - Santa Monica CA

International Classification:

G06F 1730

US Classification:

395602

Abstract:

A method for determining data structure by analyzing an outer join protocol statement used to access the data by sequentially parsing, identifying and storing each token on a push-pop stack. These steps are repeated until a join condition token is identified. The top three data are popped from the push-pop stack and represent a right database root structural node token, a join type token (left or right), and a left database structural root node token. The right and left node structures represented by the popped root node data are linked into one structure using the join type specification and the structural node points specified by the current join condition token. A root node datum representative of the resulting node structure is pushed back onto the push-pop stack. When all tokens have been processed, the node data represented by the resulting root node on the push-pop stack is ordered in accordance with the contained hierarchial data.